These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 15106298)

  • 1. The role of routine polio immunization in the post-certification era.
    Sutter RW; Cáceres VM; Mas Lago P
    Bull World Health Organ; 2004 Jan; 82(1):31-9. PubMed ID: 15106298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Poliomyelitis--why we must continue to vaccinate!].
    Windorfer A; Beyrer K
    MMW Fortschr Med; 2005 Feb; 147(8):36, 38, 40. PubMed ID: 18437859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of poliomyelitis--options and update.
    Dutta A
    Vaccine; 2008 Oct; 26(45):5767-73. PubMed ID: 18755232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission.
    Aylward RB; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):40-6. PubMed ID: 15106299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Jan; 46(RR-3):1-25. PubMed ID: 9026708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
    Sutter RW; Prevots DR; Cochi SL
    Pediatr Clin North Am; 2000 Apr; 47(2):287-308. PubMed ID: 10761505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
    Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
    Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the sequential IPV/OPV schedule on vaccination coverage levels--United States, 1997.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1998 Dec; 47(47):1017-9. PubMed ID: 9853937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.